Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 4Carcinoma, Hepatocellular 2Tuberous Sclerosis 1Recurrence 1Prostate Cancer Patients 1Neoplasms 1Lymphangioleiomyomatosis 1Glioma 1Glioblastoma 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 16Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioma × carbon-11 acetate × Clear all
NCT01961934 2016-09-28

C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression

Phoenix Molecular Imaging

Phase 2/3 Withdrawn
CNS

Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡